



## Photohuperzine A—A new photoisomer of huperzine A: Structure elucidation, formation kinetics and activity assessment

Lygia Azevedo Marques<sup>a,1</sup>, Martin Giera<sup>a,\*,1</sup>, Frans J.J. de Kanter<sup>b</sup>, Wilfried M.A. Niessen<sup>a</sup>, Henk Lingeman<sup>a</sup>, Hubertus Irth<sup>a</sup>

<sup>a</sup> VU University Amsterdam, Faculty of Sciences, BioMolecular Analysis Group, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands

<sup>b</sup> VU University Amsterdam, Faculty of Sciences, Division of Organic and Inorganic Chemistry, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands

### ARTICLE INFO

#### Article history:

Received 1 December 2009

Received in revised form 7 January 2010

Accepted 8 January 2010

Available online 20 January 2010

#### Keywords:

Huperzine A

Photoisomerization

Kinetics

Stability

NMR

### ABSTRACT

A new photoisomer of the promising “anti-Alzheimer” drug candidate ( $\pm$ ) huperzine A is described. The new substance was formed via a photoisomerization reaction and was found to be 1-amino-13-ethylidene-11-methyl-6-aza-tetracyclo-[7.3.1.0<sup>2,7</sup>.0<sup>4,7</sup>]-trideca-2,10-diene-5-one using NMR analysis. The kinetics of its formation was studied and proven to be of first-order. The described photoisomer showed a significant loss in activity, being more than 100 times less active than (–) huperzine A itself. The new substance was named photohuperzine A, referring to its photopyridone substructure.

© 2010 Elsevier B.V. All rights reserved.

## 1. Introduction

Huperzine A is a promising substance for the treatment of Alzheimer's disease (AD) [1,2]. It is a natural Acetylcholinesterase (AChE) inhibitor extracted from the club moss *Huperzia serrata* [3]. Currently, it is being used for the treatment of AD in China [4]. Furthermore, the substance is at present under a clinical phase II trial by the National Institute of Health (NIH) for the treatment of AD. The aforementioned facts underline the increasing interest in possible new huperzine A derivatives [5] or metabolites [6] as new AChE inhibitors. The racemate ( $\pm$ ) huperzine A (**1**) was first synthesized by Kozikowski [7] and Qian [8].

As **1** already entered phase II (NIH) in the drug development process, stability testing is truly one of the key issues that has to be addressed. In previous stability studies, it was shown that the analyte was highly stable under most stress conditions (e.g., pH, temperature, ionic strength, solvents) [9–12]. However, after irradiation the analyte showed significant transformation to an unknown compound. In the present study, the preparation/isolation, structure elucidation, formation kinetics, and activity determination of the new ( $\pm$ ) huperzine A (**1**) photoisomer called photohuperzine A (**2**) is reported. Photohuperzine A (**2**)

was isolated in a semi-preparative manner, employing liquid/liquid extraction and semi-preparative HPLC. The obtained substance was characterized by NMR and LC/MS.

## 2. Experimental details

### 2.1. Materials

All solvents were of HPLC grade. Methanol and acetonitrile were purchased from Biosolve (Valkenswaard, The Netherlands). Acetic acid and trifluoroacetic acid were purchased from Riedel-de-Haen (Seelze, Germany). Milli-Q water was obtained from a Milli-Q purification system, Millipore (Bedford, MA, USA). ( $\pm$ ) Huperzine A was purchased from Cfm Oskar Tropitzsch e.K (Marktredwitz, Germany). For bioassay measurements, the Acetylcholinesterase (AChE) (EC 3.1.1.7) type VI-S from *Electrophorus electricus* (electric eel) was from Sigma–Aldrich (Zwijndrecht, The Netherlands). 7-Acetoxy-1-methylquinolinium iodide (AMQI) was supplied by Fluka (Buchs, Switzerland). The enzyme and the substrate stock solutions were kept at  $-80^{\circ}\text{C}$  until use. 384 black, solid well plates were from Brand (Wertheim, Germany). All other chemicals were purchased from Sigma–Aldrich (Schnellendorf, Germany).

### 2.2. Apparatus

The Xenon lamp which was used for irradiating **1** was from AEG (Nürnberg, Germany).

\* Corresponding author.

E-mail address: [mgiera@few.vu.nl](mailto:mgiera@few.vu.nl) (M. Giera).

<sup>1</sup> These authors contributed equally to the publication.




Fig. 1. Photo-induced transformation of huperzine A (1) to photohuperzine A (2).

The degradation was followed using a Varian Cary 50 spectrophotometer (Varian, Darmstadt, Germany). All measurements were carried out at 308 nm with background correction and water was used as a blank. The liquid chromatographic (LC) analysis was performed on a Shimadzu (\*s Hertogenbosch, The Netherlands) LC20 AB quaternary pump delivering an eluent of water/acetonitrile (ACN) at 60  $\mu\text{l}/\text{min}$  (solvent A water:ACN:acetic acid:trifluoroacetic acid (95:5:0.1:0.02, v/v/v/v) and solvent B: water:ACN:acetic acid 5:95:0.1 (v/v/v)). The autosampler was a Shimadzu type SIL 20 A (injection volume 5  $\mu\text{l}$ ) and the photo-diode array detector (PDA) also was a Shimadzu (type SPD 20A). The applied column was an Ultra C18 (50 mm  $\times$  1 mm I.D.) column packed with 3  $\mu\text{m}$  particles (Restek GmbH, Bad Homburg, Germany). Chromatography was performed at 40  $^{\circ}\text{C}$  using a Shimadzu CTO 10 AC column oven. A gradient starting at 3.5% (v/v) of solvent B, ramping to 40% (v/v) B in 10 min was applied. At 10.1 min the eluent was switched to 85% (v/v) B. The analysis was stopped at 15 min. The employed mass spectrometer (MS) was a Micromass Ultima Q-TOF (Waters, Milford, MA, USA). During all experiments, the MS was operated in positive-ion electrospray ionization mode (ESI+), the capillary voltage was 2.5 kV, the source temperature 120  $^{\circ}\text{C}$ , the desolvation temperature was set at 350  $^{\circ}\text{C}$ , and the cone voltage was 35 V. Nitrogen (99.9990%) was used as the cone gas at a flow rate of 50 l/h and at 400 l/h for desolvation. MS data were acquired from  $m/z$  220 to 750.

For the semi-preparative isolation of **2**, the instrumentation consisted of two isocratic HPLC Agilent 1100 series pumps which were controlled as a single gradient LC (Agilent, Waldbronn, Germany). The autosampler was a Gilson model 234 (Villiers Le Bel, France). The separation was performed on a Waters X-Bridge C18

(100 mm  $\times$  4.6 mm I.D., 5  $\mu\text{m}$ ) column which was used in combination with a Phenomenex C18 (4 mm  $\times$  2 mm I.D., 5  $\mu\text{m}$ ) precolumn cartridge (Aschaffenburg, Germany). The temperature was held at 40  $^{\circ}\text{C}$  and the flow rate was 800  $\mu\text{l}/\text{min}$ . A gradient run starting at 6.3% (v/v) of solvent B, increasing to 18.8% (v/v) of eluent B at 5 min. This concentration was maintained for 3 min. The column effluent was monitored by UV absorption measurement (305 + 220 nm) with an Agilent 1100 series diode array detector (DAD) (Agilent, Waldbronn, Germany). All fractions were collected manually.

The high resolution MS (HRMS) data were recorded on a microToF (Bruker Daltonics, Bremen, Germany) with direct infusion in ESI+ mode. All NMR measurements were performed on a Bruker Avance 500, equipped with a cryoprobe and the residual  $\text{CHCl}_3$  signal at 7.26 ( $^1\text{H}$ ) or 77.00 ( $^{13}\text{C}$ ,  $\text{CDCl}_3$ ) ppm was used as reference.  $^1\text{H}$  NMR measurements were done at 500 MHz while the  $^{13}\text{C}$  experiments were performed at 125 MHz. The  $n\text{J}(\text{C,H})$  coupling constant used in the HMBC experiment was 8 Hz. For the bioactivity measurements, a Victor<sup>3</sup> plate reader (PerkinElmer, Waltham, MA, USA) was used.

### 2.3. Kinetics determination

To perform the kinetic determinations, a calibration curve with **1** as standard substance was generated from 10 to 250  $\mu\text{M}$  at a wavelength of 308 nm with the above described spectrophotometer. The calibration curve had the function  $y = 0.008x$  with a  $R^2$  of 0.9997. Every day, a 50  $\mu\text{M}$  sample of **1** was measured as a control. A solution of 210  $\mu\text{M}$  of **1** was prepared by dissolving 5.1 mg in 2 ml of water, adding 7  $\mu\text{l}$  of 5 M hydrochloric acid and diluting this solution up to 100.0 ml with water. All solutions were kept in Duran<sup>®</sup>

Table 1

Spectroscopic data of **2**,  $\delta$  chemical shift,  $J$  coupling constant, s singlet, d doublet, t triplet, m multiplet.

High resolution mass data $[\text{M}+\text{H}]^+$	Found: 243.1489	Calculated for $\text{C}_{15}\text{H}_{19}\text{N}_2\text{O}$ : 243.1492 (−1.2 ppm)
UV max (0.1% FA)	<220 nm	
NMR data position	$\delta$ $^{13}\text{C}$ (ppm), mult.	$\delta$ $^1\text{H}$ (ppm) ( $J$ , Hz)
		5.72 s (NH)
1	172.69, C	
2	58.93, CH	3.78 m
3	120.40, CH	6.05 m
4	162.56, C	
5	57.44, C	
6	34.81, $\text{CH}_2$	$6_{\text{eq}}$ 2.17 dd ( $^2J = 13.7, 2.8$ ) with underneath 14 <i>syn</i> ; $6_{\text{ax}}$ 2.00 dd ( $^2J = 13.7, 3.3$ )
7	35.11, CH	3.61 m
8	123.94, CH	5.43 d ( $^3J = 4.8$ )
10	12.98, $\text{CH}_3$	1.66 d ( $^3J = 6.8$ )
11	112.85, CH	5.50 q ( $^3J = 6.8$ )
12	143.18, C	
13	55.87, C	
14	45.85, $\text{CH}_2$	14 <i>anti</i> 2.29 d ( $^2J = 17$ ) 14 <i>syn</i> 2.17 d, underneath $6_{\text{eq}}$
15	134.66, C	
16	22.79, $\text{CH}_3$	1.68 s




Fig. 2. Selected HMBC correlations (C → H).

glass, which has a “natural” cut off at 310 nm according to the manufacturer’s specifications. The sample solutions were irradiated with a Xenon lamp at 150 W. In order to check for thermal degradation effects, a solution of 200  $\mu\text{M}$  **1** was wrapped in aluminum foil and irradiated under the same conditions as a blank sample (no degradation was observed over 36 h). During the kinetic determinations, a 1 ml aliquot was taken at the specified time intervals and measured with the spectrophotometer. At the time intervals  $t = 0$  h,  $t = 24$  h (only for the LC–MS measurements) and  $t = 42$  h, 75  $\mu\text{l}$  of the sample solution was diluted to 1.0 ml with solvent A and additionally analyzed by LC–MS and LC–PDA. All calculations were done with Graph Pad Prism 4.

#### 2.4. Synthesis and extraction of photohuperzine (**2**)

The sample of **2** applied in structure elucidation by NMR was generated by irradiation of two separate reaction batches of 5 mg of **1** in 100.0 ml of water, acidified with 7  $\mu\text{l}$  of 5 M HCl for 24 h. The solutions were alkalinized with a few drops (approximately 200  $\mu\text{l}$ ) of an aqueous 5 M sodium hydroxide solution and extracted with three portions of 20 ml of dichloromethane (DCM). The combined organic layers were washed carefully with 20 ml of water. The organic phase was dried over anhydrous magnesium sulphate, filtered and evaporated to dryness under a gentle stream of nitrogen. The resulting residue was dissolved in  $2 \times 500$   $\mu\text{l}$  of eluent A and 100  $\mu\text{l}$  portions were subsequently injected into the specified LC system for a semi-preparative sample clean-up. The collected fractions (~50 ml) were pooled and the DCM extraction was repeated, the solid residue was dried under vacuum. For the material used for




Fig. 3. Selected NOESY correlations.

the bioassay, the semi-preparative HPLC clean-up procedure was repeated and 130  $\mu\text{g}$  of pure **2** were obtained (see supplementary material S1).

#### 2.5. Acetylcholinesterase (AChE) fluorescence-based assay

A 4 mM stock solution of **2** in 0.1% formic acid (FA) was prepared from the purified material and used for further dilutions. The AChE bioactivity assay was measured in a 384 black, solid well plate using AChE (EC 3.1.1.7) (0.1 U/ml) from electric eel dissolved in 20 mM Tris–HCl buffer pH 7.5, 2 g/l PEG 6000 and 1 g/l ELISA blocking reagent. As substrate, AMQI 2  $\mu\text{M}$  in 50 mM of citrate buffer at pH 5 was used. 2  $\mu\text{l}$  of a solution containing **2** (4 mM, 0.8 mM) in 0.1% (v/v) FA were mixed with 40  $\mu\text{l}$  of the enzyme solution. After 5 min of incubation, 40  $\mu\text{l}$  of the substrate solution were added. The final concentrations for enzyme and substrate were 0.05 U/ml and 1  $\mu\text{M}$ , respectively. The final concentrations of **2** were 100 and 20  $\mu\text{M}$ , respectively. The fluorescence intensity was measured after a reaction time of 2 min using a Victor<sup>3</sup> plate reader at 405 nm and 520 nm for excitation and emission, respectively. As positive control, a solu-




Fig. 4. MM2 energy minimized structures of huperzine A (left) and photohuperzine A (right), nitrogen atoms are labeled blue, oxygen red and free electron pairs pink, the dotted lines show the measured distances between the NHCO group and protons H-8 and H-16.

tion of 160  $\mu\text{M}$  (–) huperzine A (2  $\mu\text{M}$  final concentration) was used.

### 3. Results and discussion

#### 3.1. Synthesis and extraction of photohuperzine A (**2**)

After the initial detection of the new huperzine A derivative, the solute was prepared and isolated for a complete structure elucidation. The reaction (Fig. 1) yielded 18% of >95% (LC/MS) pure photohuperzine A (**2**). This material was used for all further spectroscopic analyses.

#### 3.2. Structure elucidation

The commonly accepted biosynthetic numbering of **1** [13] was also applied to **2** (see Fig. 1) and is used in discussing the interpretation of the NMR data below. In LC–MS and HRMS, the compounds **1** and **2** are found to be isomers (elemental composition  $\text{C}_{15}\text{H}_{19}\text{N}_2\text{O}$ ). The LC–MS spectra of **1** showed a much stronger fragment ion with  $m/z$  226  $[\text{M}+\text{H}-\text{NH}_3]^+$  than **2** (see supplementary material S2 and S3). Additional MS/MS measurements did not provide any insights into the structure of **2**.

The UV spectrum of **1** showed the typical 2-pyridon absorption, having a maximum at 308 nm, whereas the UV spectrum of **2** completely lacks this absorption maximum. These findings were leading to the assumption that photoisomerization involving the 2-pyridone substructure of **1** had occurred. Photoreaction of




Fig. 5. Bioactivity of **2** compared to (–) huperzine A, the error bars show 1 SEM;  $n=3$ .

2-pyridones is a well known process leading to valence isomerization in dilute solutions, thereby forming so called photopyridones [14,15].

The structure of **2** was further elucidated by  $^1\text{H}$ ,  $^{13}\text{C}$ , APT, HSQC, COSY, HMBC and NOESY NMR measurements. In Table 1, the spectroscopic data are summarized. Figs. 2 and 3 show the most important HMBC and NOESY correlations.





Fig. 6. Comparison of LC–MS and LC–PDA data, left LC–MS extracted ion chromatogram (24 h)  $m/z$  226 + 243, right LC–PDA chromatogram (42 h) 308 nm, (**1**) huperzine A and (**2**) photohuperzine A.



**Fig. 7.** First-order (logarithmic) photodegradation of (±) huperzine A, upper right corner, UV absorbance spectra at different time points, the arrow indicates the measurement wavelength (308 nm).

The *trans*-(*E*) configuration of the 11(12) double bond was proven by the NOESY coupling of H-10 with H-7. The conformation with the NHCO group standing “upwards” into the direction of the 16-CH<sub>3</sub> group could be underlined by the corresponding NOESY correlations between the NH group and protons H-16 and H-8. The distance for both correlations was measured (Chem 3D pro 11.0, Cambridgesoft) from the MM2 energy minimized structure of **2** and determined to be 3.1 Å for both. The distance between the NHCO group and protons H-16 and H-8 in the huperzine A molecule (**1**) originally was 6.0 and 4.7 Å, respectively. This proves for the fact that these protons due to the photoisomerization got much closer in space (see Fig. 4). The 2D spectra can be found in the supporting information S4–S7.

### 3.3. Inhibitory activity

In order to test the inhibitory activity of **2**, a high purity sample was necessary because huperzine A itself is a very strong Acetylcholinesterase (AChE) inhibitor [16] having an IC<sub>50</sub> of 460 nM [17]. On the other hand, **2** did not show any significant AChE inhibition up to a concentration of 100 μM. As a result, it is at least 100 times less potent than **1** itself (Fig. 5). A reason for this dramatic loss in activity can be given by comparing the MM2 (Chem 3D pro 11.0, Cambridgesoft, default settings) energy minimized structures of **1** and **2** (Fig. 4). It can be seen that forming the photopyridon substructure severely alters the planarity of the original 2-pyridon part of the molecule. In addition, this part of the molecule also loses its aromatic character. Overall, the investigated double bond isomerization leads to severe changes in the conformation of the molecule, which possibly explains the loss of activity. An in depth description of the interactions between (±) huperzine A and its target enzyme can be found in the literature [18,19].

### 3.4. Kinetics of formation

As can be seen from Fig. 6, none of the formed photoproducts shows a significant absorption at 308 nm. Next to the formation of the new photoisomer **2**, the LC–MS data revealed the occurrence of

a minor photoproduct with a retention time of 11.5 min. This substance was not investigated further during this study as its present amount was not sufficient for characterization. The strong baseline drift in the PDA chromatogram can be explained by the fact that trifluoroacetic acid was only present in eluent A.

Fig. 7 shows that the photodegradation of **1** is following first-order kinetics, with the equation  $\ln c = \ln c_0 - kt$ , where  $c$  (μM) is the concentration at time  $t$  (h),  $c_0$  is the starting concentration and  $k$  is the rate constant (h<sup>-1</sup>). This means that  $k$  is equal to the slope of the obtained plot. Under the described experimental conditions, the regression coefficient ( $R^2$ ) for the logarithmic plot was determined to be 0.9912, while  $k$  was  $-0.03331 \pm 0.0005161 \text{ h}^{-1}$ .

## 4. Conclusion

The study presents a new photo-derivative of (±) huperzine A (**1**) generated after irradiation with a Xenon lamp using wavelengths of 310 nm and higher. Formation of the photoisomer, named photohuperzine A (**2**), followed first-order kinetics, as expected for a photodegradation reaction. The new substance was formed by a photoisomerization reaction leading to a photopyridone type of structure possessing a β-lactam substructure. The bioactivity assessment with an AChE assay showed the poor activity of **2** against the target enzyme AChE having at least a 100 times lower bioactivity than (–) huperzine A. A likely explanation for this is the significant difference in the molecular conformation between the two compounds. Overall, the photoreactivity determined for **1** has to be considered for its storage conditions and future studies.

## Acknowledgements

M. Giera was supported by the German Academic Exchange Programme (DAAD) and L. Azevedo Marques was supported by the Alban programme, the European Union programme of high level scholarships for Latin America (scholarship E06D102010BR).

## Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.jpba.2010.01.013.

## References

- [1] J. Patocka, *Acta Medica (Hradec Kralove)* 41 (1998) 155–157.
- [2] R. Wang, X.C. Tang, *Neurosignals* 14 (2005) 71–82.
- [3] J.S. Liu, Y.L. Zhu, *Can. J. Chem.* 64 (1986) 837–839.
- [4] X. Ma, C. Tan, D. Zhu, D.R. Zhu, P. Xiao, *J. Ethnopharmacol.* 113 (2007) 15–34.
- [5] A.P. Kozikowski, G. Campiani, A. Saxenac, B.P. Doctor, *J. Chem. Soc. Chem. Commun.* (1995) 283–285.
- [6] M. Xiaochao, W. Haixue, X. Jian, Z. Ting, T. Zenghong, *Eur. J. Pharmacol.* 461 (2003) 89–92.
- [7] A.P. Kozikowski, Y. Xia, E.R. Reddy, W. Tuckmantel, I. Hanin, X.C. Tang, *J. Org. Chem.* 56 (1991) 4636–4645.
- [8] L. Qian, R. Ji, *Tetrahedron Lett.* 30 (1989) 2089–2090.
- [9] Y. Ashani, J.O. Peggins III, B.P. Doctor, *Biochem. Biophys. Res. Commun.* 184 (1992) 719–726.
- [10] G. Wei, S. Xiao, R. Lu, C. Liu, *J. Chromatogr. B* 830 (2006) 120–125.
- [11] J. Ye, S. Zeng, W. Zhang, G. Chen, *J. Chromatogr. B* 817 (2005) 187–191.
- [12] Y. Wang, D. Chua, J. Gu, J.P. Fawcett, Y. Wu, W. Liu, *J. Chromatogr. B* 803 (2004) 375–378.
- [13] M. Niemitz, R. Laatikainen, S.N. Chen, R. Kleps, A.P. Kozikowski, G. Pauli, *Magn. Reson. Chem.* 45 (2007) 878–882.
- [14] R. Matsushima, K. Terada, *J. Chem. Soc. Perkin Trans. II* (1985) 1445–1448.
- [15] H. Hongo, K. Iwasa, C. Kabuto, H. Matsuzaki, H. Nakano, *J. Chem. Soc. Perkin Trans. I* (1997) 1747–1754.
- [16] R. Wang, H. Yan, X.C. Tang, *Acta Pharmacol. Sin.* 27 (2006) 1–26.
- [17] C.F. de Jong, R.J.E. Derks, B. Bruyneel, W.M.A. Niessen, H. Irth, *J. Chromatogr. A* 1112 (2006) 303–310.
- [18] M.L. Raves, M. Harel, Y.P. Pang, I. Silman, A.P. Kozikowski, J.L. Sussman, *Nature Struct. Biol.* 4 (1997) 57–63.
- [19] H. Dvir, H.L. Jiang, D.M. Wong, M. Harel, M. Chetrit, X.C. He, G.Y. Jin, G.L. Yu, X.C. Tang, I. Silman, D.L. Bai, J.L. Sussman, *Biochemistry* 41 (2002) 10810–10818.